Cardio-oncology
7
3
3
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (7)
JUdicious Surveillance for Trastuzumab Induced Cardiotoxicity in the First Year
Structured Cardio-Oncology Rehabilitation for Cardiovascular Outcomes in Cancer Survivors
Immune Checkpoint Inhibitor Therapy for Cancer and Risk of Myocarditis or Cardiomyopathy
Cardio-Oncology Rehabilitation Care Process
Early Identification and Evaluation of Cyclophosphamide Cardiotoxicity
Prevention and Pharmacological Management of Cardiac Adverse Drug Reactions Induced by Drugs Used in Oncology.
Vascular Functions in Myeloma Patients During Anti-tumor Therapy